Delisting riskPopularity #4,119
AEON Biopharma (AEON)
Develops a therapeutic Botox biosimilar candidate for broad-label use.
$0.2724
vs last close+0.01 (+3.97%)
Something off on this page? Send us feedback.
13F · 13D/G · Form 4
| Institutions | 28.99% | 12.80M shares | |
|---|---|---|---|
| 23 holders · as of Jun 30, 2026 | |||
| Insiders | 14.72% | 6.50M shares | |
| 1 holder · as of Aug 21, 2026 | |||
| Other | 56.29% | 24.86M shares | |
| remainder | |||
44.16M company shares as of Aug 21, 2026 · institutions as of Jun 30, 2026 · holders as of their latest filing
13F, as of Jun 30, 2026
23 holders · 12.80M shares · 3 new positions · 9 increased · 1 reduced · 4 closed
| Holder | Shares | % outstanding | Chg q/q | Filed |
|---|---|---|---|---|
| Dauntless Investment Group, LLC | 12.49M | 28.28% | +9.96M | Aug 13, 2026 |
| Geode Capital Management, LLC | 95.3K | 0.22% | +8.2K | Aug 12, 2026 |
| Vanguard Capital Management LLC | 90.5K | 0.21% | 0 | Aug 13, 2026 |
| Blue Owl Capital Holdings LP | 42.4K | 0.10% | 0 | Aug 11, 2026 |
| Formidable Asset Management, LLC | 20.0K | 0.05% | 0 | Jul 17, 2026 |
| Stonex Group Inc. | 19.0K | 0.04% | +19.0Knew | Aug 12, 2026 |
| Vanguard Fiduciary Trust Co | 13.7K | 0.03% | −989 | Aug 13, 2026 |
| LPL Financial LLC | 11.5K | 0.03% | 0 | Aug 7, 2026 |
13D/G · 5% or more, as filed
No 13D/G filer at 5% or more on record.
Form 4
Latest trades
| Date | Insider | Type | Shares | Avg price | Owned after |
|---|---|---|---|---|---|
| Aug 19, 2026 | Timothy P. Lynch10 percent owner | Purchase | 1,150,000 | $0.2117 | 6,500,000 |
House and Senate disclosures
Not reported.